Plain-English translation of NCT07511257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a combination of one blood clot prevention medication (clopidogrel) plus rivaroxaban—an anticoagulant that helps prevent clots—works better than the standard two blood clot prevention medications (aspirin and clopidogrel) for people who have had a heart attack with an unusually enlarged coronary artery. The study is trying to figure out which medication strategy keeps patients safest after this type of heart attack.
People with enlarged coronary arteries are at higher risk for blood clots and serious complications after a heart attack. Doctors aren't yet sure which medication approach—the current standard two-medication strategy or the newer single medication plus anticoagulant approach—better prevents clots in this specific situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to take either the standard two-medication combination or the new single medication plus anticoagulant strategy. You will take your assigned medications daily by mouth. The study will track how well the medication prevents future heart problems, blood clots, and side effects, likely through hospital visits and follow-up appointments over several months.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Mexico